StockData
Arcutis Biotherapeutics, Inc. logo

Arcutis Biotherapeutics, Inc. (ARQT) stock

ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/30403% above fair value
$27.61+0.28 (+1.02%)

Close on Nov 18, 2026Market cap $3.47BP/E 125.5Yield –

Arcutis Biotherapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Arcutis Biotherapeutics's operating income for the twelve months ending Jun 30, 2026 was $34.25M. For fiscal 2025 it was -$12.23M. The highest annual figure on record is -$12.23M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$12.23M–
FY2024Dec 31, 2024-$128.40M–
FY2023Dec 31, 2023-$241.10M–
FY2022Dec 31, 2022-$301.63M–
FY2021Dec 31, 2021-$206.53M–
FY2020Dec 31, 2020-$136.65M–
FY2019Dec 31, 2019-$43.13M–
FY2018Dec 31, 2018-$19.74M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$16.43M–
Q1 FY2026Mar 31, 2026-$9.09M–
Q4 FY2025Dec 31, 2025$18.39M–
Q3 FY2025Sep 30, 2025$8.53M–
Q2 FY2025Jun 30, 2025-$14.61M–
Q1 FY2025Mar 31, 2025-$24.53M–
Q4 FY2024Dec 31, 2024-$7.63M–
Q3 FY2024Sep 30, 2024-$39.07M–
Q2 FY2024Jun 30, 2024-$50.08M–
Q1 FY2024Mar 31, 2024-$31.62M–
Q4 FY2023Dec 31, 2023-$61.17M–
Q3 FY2023Sep 30, 2023-$36.90M–
Q2 FY2023Jun 30, 2023-$66.76M–
Q1 FY2023Mar 31, 2023-$76.27M–
Q4 FY2022Dec 31, 2022-$68.42M–
Q3 FY2022Sep 30, 2022-$104.75M–
Q2 FY2022Jun 30, 2022-$65.83M–
Q1 FY2022Mar 31, 2022-$62.63M–
Q4 FY2021Dec 31, 2021-$71.29M–
Q3 FY2021Sep 30, 2021-$57.08M–
Q2 FY2021Jun 30, 2021-$42.08M–
Q1 FY2021Mar 31, 2021-$36.09M–
Q4 FY2020Dec 31, 2020-$34.06M–
Q3 FY2020Sep 30, 2020-$38.30M–
Q2 FY2020Jun 30, 2020-$35.63M–
Q1 FY2020Mar 31, 2020-$28.65M–
Q4 FY2019Dec 31, 2019-$12.99M–
Q3 FY2019Sep 30, 2019-$14.65M–
Q2 FY2019Jun 30, 2019-$8.54M–
Q1 FY2019Mar 31, 2019-$6.95M–

More Arcutis Biotherapeutics figures

See a number that looks wrong?